Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

RCT (n=289, Brazil) reported tofacitinib led to lower risk of death or respiratory failure through day 28 than placebo (cumulative incidence 18.1% vs. 29.0%; risk ratio, 0.63; 95% CI, 0.41 to 0.97; p=0.04). Serious adverse events occurred in 14.1 vs 12.0%, respectively.

New England Journal of Medicine